ADVFN Logo
Boards:
    Quotes:
      Boards
      News
      Market Data
      Markets
      Discover
      Subscribe Login/Register Profile Icon
      S&P 500
      5,567.19
      1.06%
      US Tech 100
      19,828.00
      0.95%
      Dow Jones
      39,375.87
      0.17%
      Brent Oil
      86.775
      0.00%
      Bitcoin
      57,272.90
      -1.76%
      Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
      Get Started
      1. Home
      2. Investing
      3. Stocks
      4. USA
      5. NASDAQ
      6. Marker Therapeutics Inc (MRKR)

      7. Marker Therapeutics Inc (MRKR) News

      Marker Therapeutics Inc

      Marker Therapeutics Inc (MRKR)

      NASDAQ
      4.97
      -0.155
      (-3.02%)
      Closed July 07 4:00PM
      Delayed by 15 minutes
      4.8116
      -0.1584
      (-3.19%)
      After Hours: 7:59PM
      Delayed by 15 minutes

      Empower your portfolio: Real-time discussions and actionable trading ideas.

      Premium

      MRKR News

      Official News Only

      Form 8-K - Current report
      Edgar (US Regulatory)
      June 12 2024
      MRKR (-3.02%)

      Form 8-K - Current report
      Edgar (US Regulatory)
      May 15 2024
      MRKR (-3.02%)

      Form 10-Q - Quarterly report [Sections 13 or 15(d)]
      Edgar (US Regulatory)
      May 15 2024
      MRKR (-3.02%)

      Form 8-K - Current report
      Edgar (US Regulatory)
      March 01 2024
      MRKR (-3.02%)

      Form 8-K - Current report
      Edgar (US Regulatory)
      February 26 2024
      MRKR (-3.02%)

      Form 8-K - Current report
      Edgar (US Regulatory)
      January 08 2024
      MRKR (-3.02%)

      Form 8-K - Current report
      Edgar (US Regulatory)
      December 11 2023
      MRKR (-3.02%)

      MRKR Discussion

      View Posts
      microcapbiotech microcapbiotech 6 days ago
      Message to whoever has been buying the dips for the last couple of weeks, slowly raising the share price.
      KEEP DOING THAT.
      Thank You
      👍️0
      PonkenPlonken PonkenPlonken 2 weeks ago
      They scoop it up and then sit tightly on the bid after MRKR terminated ATM offering with July ph2 data around and you guys just leave it at that?

      Nobody talks data?
      👍️0
      KeithamdMIC KeithamdMIC 3 weeks ago
      Hi micro I think your correct. To try and average to a lower break even share price I would think buying shares now would be the key. The news has been somewhat positive on MRKR but it seems that MRKR hasn’t convinced many that the product is viable for those suffering without much hope for remission with traditional medicine. As always when your down somewhat like gambling it’s either walk away or buy more now to swing your share price lower to get back or maybe get in the black with your initial investment. Good luck to all who have been here for years.
      👍️ 1
      PonkenPlonken PonkenPlonken 3 weeks ago
      11$ is my first target for the readout/potential partner looming. HUUGE Platform.
      Triple digits are possible but assess step by step.
      👍️0
      microcapbiotech microcapbiotech 3 weeks ago
      Hello, triple digits may be hard, if everything goes perfect for a few more years, then maybe, sorry, just trying to be somewhat rational.
      Great news might bring $20+ in a short time , above $50 would need a TON of revenue I would think.
      👍️0
      KeithamdMIC KeithamdMIC 3 weeks ago
      I’ve been in this roller coaster for a long time as have Phantom and micro etc. Mostly going down rapidly and up at times very slowly. How do we come back from a 10 to 1 reverse split. I’m sure there are many more that had more shares than I had of MRKR before the reverse split. For me even if MRKR gets bought out the share price would have to hit triple digits a share to break even. I can’t see that happening. Does anyone else?
      👍️0
      PonkenPlonken PonkenPlonken 3 weeks ago
      get it--- a deal is coming until then price is like a painting in the rain
      keep in mind ph2 readout is coming
      YUUGE platform
      👍️0
      microcapbiotech microcapbiotech 3 weeks ago
      Now, can we keep climbing? Hope so.
      👍️0
      PonkenPlonken PonkenPlonken 3 weeks ago
      what are you referring to ?
      👍️0
      learningcurve2020 learningcurve2020 3 weeks ago
      Looks like the one always calling it right gets ignored the most here. Seems to be an investment strategy on many of these iHub boards. LOL
      💩 1 🤡 1
      PonkenPlonken PonkenPlonken 3 weeks ago
      Given the 8-K---- Wont stay single for much longer. Makes a lot of sense their PFS results and MultiTAA
      Own 7k shares
      👍️ 1
      learningcurve2020 learningcurve2020 3 weeks ago
      Still no reason to cancel it. Vera may have in his mind to move to the OTC for further cost cutting. The ATM probably can't be used there.

      >>Hopefully this is an indicator that they aren't worried about where the next capital raise is coming from
      👍️0
      Buckboard Buckboard 3 weeks ago
      Thanks Joby and PL
      👍️0
      Phantom Lord Phantom Lord 3 weeks ago
      I thought that was pretty interesting also. I could be missing something but it seems odd to terminate it when they could just keep it active but not use it. I'm glad it's gone since I hate ATMs anyways but I still think it's weird as it somewhat acts as a safety net. Hopefully this is an indicator that they aren't worried about where the next capital raise is coming from or at the very least they will have some buyers lined up.
      👍️ 1
      jobynimble jobynimble 3 weeks ago
      Results of two proposals plus this…

      Item 8.01 Other Events.

      On June 10, 2024, the Company provided notice of its termination of that certain Controlled Equity OfferingSM Sales Agreement, or the ATM Agreement, with Cantor Fitzgerald & Co. and RBC Capital Markets, LLC, or the Sales Agents, pursuant to which the Company could offer and sell, from time to time at its discretion through the Sales Agents, shares of its common stock having an aggregate offering price of up to $75.0 million. (the “ATM Offering Program”). The Company is not subject to any termination penalties related to the termination of the ATM Agreement.
      👍️ 2
      jobynimble jobynimble 3 weeks ago
      8-K out: https://www.sec.gov/ix?doc=/Archives/edgar/data/1094038/000110465924070830/tm2416968d1_8k.htm
      👍️ 1
      PonkenPlonken PonkenPlonken 4 weeks ago
      again a higher low. Think they start frontrunning the readout.
      👍️0
      PonkenPlonken PonkenPlonken 4 weeks ago
      higher lows and some volume
      👍️0
      PonkenPlonken PonkenPlonken 1 month ago
      things are coming together here
      maybe there is an announcement together here. Dont get why its single given the stellar data .
      👍️0
      InvestorCpt InvestorCpt 1 month ago
      Yeah.... I've had better days
      👍️0
      Buckboard Buckboard 1 month ago
      Yes, now we are all rich.
      👍️ 1
      microcapbiotech microcapbiotech 1 month ago
      ARE WE ALL RICH YET?
      👍️0
      PonkenPlonken PonkenPlonken 1 month ago
      july p2, excuse me.
      I think it will run earlier in anticipation and/or it doesnt stay single for much longer.
      👍️0
      Phantom Lord Phantom Lord 1 month ago
      No indications we will see any new data in June.
      👍️0
      learningcurve2020 learningcurve2020 1 month ago
      Like I said, the company needs to be acquired quickly based on inside knowledge the data looks really promising, or it's over current shareholders.
      👍️0
      PonkenPlonken PonkenPlonken 2 months ago
      has a loyal buyer. think the june data will make it go, they have outstanding data. Multitarget mutations!
      👍️0
      microcapbiotech microcapbiotech 2 months ago
      Phantom, Thank You for contacting JV and filling us in. Your timeline for event seems the most reasonable.
      I think our main problem is, Nobody has heard of MRKR, Doctors, Patients, Investors.
      I have not and will not sell a single share, but I kind of give up trying to figure this price.
      3 patients, 2 great news and 1 good news, AND IT DOES BASICALLY NOTHING ???
      Have a great summer.
      👍️0
      Phantom Lord Phantom Lord 2 months ago
      That's always my biggest question also. I don't want to be diluted to hell. Every time I bring it up I get the same answer which is the company fully believes they can make it to the end of 2025 with what they have. I was originally skeptical that they could make it that far but the 10Qs do seem to back them up as they have got their spending in check.

      There is a 99% chance we experience some dilution but I previously spoke to Vera about this and he said it would be done on the back of a news release. My guess would be the final lymphoma data which shouldn't be too long. IMO, early next year at the latest but we'll see when we get the enrollment update.

      If the results there are not enough to gain som major SP appreciation then the dilution will be the least of our worries.
      👍️0
      jueles14 jueles14 2 months ago
      Thanks. Vera still working on his CEO communication skills I see haha. Big Q for me as with all biotechs is funding, i.e., can they produce enough good data in the near-term to keep going w/o excessive dilution. I can wait til Q4 if the data’s good; if the H2 data lets down or is still too small sample, we could be in trouble, we’ll see.
      👍️0
      learningcurve2020 learningcurve2020 2 months ago
      They're a disaster. Zero energy coming from this company. It feels empty. Without a quick buyout this thing is toast, IMO.
      👍️0
      Buckboard Buckboard 2 months ago
      Thanks
      👍️0
      Phantom Lord Phantom Lord 2 months ago
      I reached out to clarify if we would be getting data in the summer like previously stated or if it would be the "2nd half" of the year which I will generally equate to the latter half of the year. The answer was just 2nd half of the year so I will stick to my assumption that we will get lymphoma data sometime in Q4. My biggest question is if it will be interim or the final readout as I was previously led to believe we could have final data by then. We'll see I guess.

      Additionally, I was told they are planning a research event sometime in July where they should provide more updates. Details on that should be provided sometime next month I would assume.

      So as of now we have this supposed research event, lymphoma data, and the initiation of the Off the Shelf MT401 AML trial to look forward to for the rest of the year. Always a shot at pancreatic updates but the standard announcement on that is they are waiting for grant funds or other non dilutive funds before initiating so I won't count on that news right now
      👍️0
      learningcurve2020 learningcurve2020 2 months ago
      This company filed a 13g

      https://www.nea.com/team?unit=operations#filters
      💩 1 🤡 1
      PonkenPlonken PonkenPlonken 2 months ago
      The buyer never really left here and has excellent data, no cytox..
      👍️0
      InvestorCpt InvestorCpt 2 months ago
      I hope it's just that and not a delay or mediocre results prompting them to keep it quiet
      👍️ 1
      Phantom Lord Phantom Lord 2 months ago
      That's my fear is that they will use those two patients as a cop out. Last I spoke with Vera he said there would be a data release over summer inn addition to this 2 patient release. Technically 2nd half of the year could be summer so I hope they stick to it. I'll follow up if I get clarification.
      👍️ 1
      jueles14 jueles14 2 months ago
      If you do reach out I’d be curious to hear what they say. I suppose technically Vera can say he shared data H1 because we know about those two additional patients, but obviously we were all hoping for more. Slow enrollment might be the culprit; drug seems to be working 🤞 just need to get it to more ppl / stack up the data.
      👍️0
      Phantom Lord Phantom Lord 2 months ago
      That is the only thing I can think of. I plan on reaching out to see if I can get a clear answer but I don't see any other reason for the delay unless they completely filled the trial and are deciding to just wait until all data is available. I was previously told full trial data should be available by the end of the year.
      👍️0
      InvestorCpt InvestorCpt 2 months ago
      What could be delaying this now? Slow enrollment?
      👍️0
      Buckboard Buckboard 2 months ago
      Thanks, as always
      👍️0
      InvestorCpt InvestorCpt 2 months ago
      I see that now.... Seems the only hope for sustaining SP short term would be a grant or something else to fund pancreatic
      👍️0
      microcapbiotech microcapbiotech 2 months ago
      Thank You
      👍️0
      Phantom Lord Phantom Lord 2 months ago
      They quietly changed data release from 1st half of the year to the 2nd half. At this point I would be surprised if they release any lymphoma data in June and even more surprised if they ever stick to their original timelines.
      👍️ 2
      microcapbiotech microcapbiotech 2 months ago
      I think so but not positive. It may just be a rehash of what they just gave us.
      👍️0
      Buckboard Buckboard 2 months ago
      Thanks
      👍️0
      InvestorCpt InvestorCpt 2 months ago
      Aren't we expecting some new data in June?
      👍️0
      microcapbiotech microcapbiotech 2 months ago
      Cash looks OK also:
      Cash Position and Guidance: At March 31, 2024, Marker had cash and cash equivalents of $11.3 million. The Company believes that its existing cash and cash equivalents will fund its operating expenses into the fourth quarter of 2025, inclusive of available drawdowns from grant funds.
      👍️0
      microcapbiotech microcapbiotech 2 months ago
      It all sounds good so far, 3 patients, 3 for 3 good results.
      First study participant treated with MT-601 had diffuse large B cell lymphoma (DLBCL) and failed four prior lines of therapy, including a relapse within 90 days of anti-CD19 CAR T cell therapy (Breyanzi) (PRESS RELEASE, JUNE 12, 2023). Without prior lymphodepletion, this participant achieved a complete response eight weeks after the second infusion of MT-601 and remains in complete response nine months after initial treatment with MT-601 (PRESS RELEASE, APRIL 8, 2024).
      Another study participant had transformed follicular Non-Hodgkin’s Lymphoma (NHL) and failed 12 lines of therapy, including bispecific T cell engager therapy (mosunetuzumab) for follicular NHL, and anti-CD19 CAR T cells (Yescarta) after transformation into DLBCL. At the time of MT-601 infusion, only follicular NHL persisted in this patient. Eight weeks after initial infusion with MT-601 without prior lymphodepletion, the study participant achieved a complete response, which remains three months following treatment with MT-601(PRESS RELEASE, APRIL 8, 2024).
      The third study participant treated had DLBCL with cutaneous involvement and was not eligible for CAR T cell therapy. This participant achieved a partial response eight weeks after MT-601 treatment without prior lymphodepletion with all lesions decreasing in size including one that has completely resolved (PRESS RELEASE, APRIL 8, 2024).
      Treatment was well tolerated among all patients with no significant treatment-related adverse events including cytokine release syndrome or neurotoxicity.
      👍️0
      microcapbiotech microcapbiotech 2 months ago
      Press Release:
      https://ir.markertherapeutics.com/news-releases/news-release-details/marker-therapeutics-reports-first-quarter-2024-financial-results
      👍️0
      learningcurve2020 learningcurve2020 2 months ago
      How about a buyout instead just to put retail out of their misery.
      👍️0

      Your Recent History

      NASDAQ
      MRKR
      Marker Therapeutics
      Delayed Upgrade Clock